Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Protagonist Therapeutics reports Q2 EPS (59c), consensus (59c) » 16:08
08/06/20
08/06
16:08
08/06/20
16:08
PTGX

Protagonist Therapeutics

$16.38 /

-0.21 (-1.27%)

Reports Q2 revenue $6.2M,…

Reports Q2 revenue $6.2M, consensus $2.53M. "We have succeeded in bringing three differentiated candidates from de novo discovery into Phase 2 development," commented CEO Dinesh Patel. "Each of these candidates has unique attributes that address specific unmet needs in diverse diseases, such as blood disorders with PTG-300 and inflammatory bowel disease with PTG-200 and PN-943. The hepcidin mimetic PTG-300 makes use of the iron homeostasis mechanism of a natural hormone and has demonstrated potential in the treatment of polycythemia vera. We expect to initiate a pivotal study for PTG-300 in 2021 after discussions with the regulatory agencies. PN-943 and PTG-200 are both oral, gut-restricted candidates for the potential treatment of inflammatory bowel disease. PTG-200 is an IL-23 receptor antagonist partnered with Janssen and is currently in a Phase 2 Crohn's study. We recently initiated screening of patients for our Phase 2 study of PN-943 in ulcerative colitis. Finally, we are well financed and recently raised $122M through a successful secondary offering and use of our ATM program, which enables us to support planned operations through mid-2023."

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$16.38 /

-0.21 (-1.27%)

PTGX Protagonist Therapeutics
$16.38 /

-0.21 (-1.27%)

07/15/20 Jefferies
Protagonist Therapeutics initiated with a Buy at Jefferies
05/18/20 H.C. Wainwright
Protagonist Therapeutics price target raised to $28 from $23 at H.C. Wainwright
05/11/20 Nomura Instinet
Protagonist Therapeutics price target raised to $33 from $29 at Nomura Instinet
04/30/20 Nomura Instinet
Protagonist shares offer 'asymmetric potential upside,' says Nomura Instinet
PTGX Protagonist Therapeutics
$16.38 /

-0.21 (-1.27%)

  • 12
    May
PTGX Protagonist Therapeutics
$16.38 /

-0.21 (-1.27%)

Over a week ago
Initiation
Protagonist Therapeutics initiated with a Buy at Jefferies » 06:47
07/15/20
07/15
06:47
07/15/20
06:47
PTGX

Protagonist Therapeutics

$15.54 /

+0.37 (+2.44%)

Jefferies analyst Chris…

Jefferies analyst Chris Howerton initiated coverage of Protagonist Therapeutics with a Buy rating and $27 price target. He projects Protagonist's lead asset, PTG-300, can grow to over $1.6B in peak sales in its lead indication, polycythemia vera, alone, using "conservative estimates," Howerton tells investors. The analyst, who models a potential approval in 2025 for the drug, adds that upside for PTG-300 could come from a hereditary hemochromatosis indication.

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$15.54 /

+0.37 (+2.44%)

PTGX Protagonist Therapeutics
$15.54 /

+0.37 (+2.44%)

05/18/20 H.C. Wainwright
Protagonist Therapeutics price target raised to $28 from $23 at H.C. Wainwright
05/11/20 Nomura Instinet
Protagonist Therapeutics price target raised to $33 from $29 at Nomura Instinet
04/30/20 Nomura Instinet
Protagonist shares offer 'asymmetric potential upside,' says Nomura Instinet
01/07/20 BTIG
Sarepta, Pacira, Protagonist named top 2020 Biotech picks at BTIG
PTGX Protagonist Therapeutics
$15.54 /

+0.37 (+2.44%)

  • 12
    May
PTGX Protagonist Therapeutics
$15.54 /

+0.37 (+2.44%)

Over a month ago
Hot Stocks
Protagonist Therapeutics receives Orphan Drug Designation for PTG-300 » 05:00
06/18/20
06/18
05:00
06/18/20
05:00
PTGX

Protagonist Therapeutics

$16.18 /

-0.2 (-1.22%)

Protagonist Therapeutics…

Protagonist Therapeutics announced that the FDA has granted Orphan Drug Designation for PTG-300 for the treatment of polycythemia vera. PTG-300 is an injectable synthetic peptide mimetic of the natural hormone hepcidin currently in clinical development for the treatment of polycythemia vera and hereditary hemochromatosis. "Receiving FDA orphan drug designation is another important milestone for Protagonist and underscores the importance of our work in polycythemia vera," commented Samuel Saks, M.D., Protagonist Chief Medical Officer. "Individuals living with polycythemia vera face a high disease burden. PTG-300 has a non-cytoreductive therapeutic mechanism in the treatment of polycythemia vera and has shown a well-tolerated safety profile to date. Because of its properties, PTG-300 may help provide sustained control of hematocrit and potentially help address symptoms of polycythemia vera and systemic iron deficiency in these patients." Protagonist recently announced initial Phase 2 results in patients with polycythemia vera that demonstrated robust clinical response and clinically meaningful dose related control of hematocrit levels on individual patient basis.

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$16.18 /

-0.2 (-1.22%)

PTGX Protagonist Therapeutics
$16.18 /

-0.2 (-1.22%)

05/18/20 H.C. Wainwright
Protagonist Therapeutics price target raised to $28 from $23 at H.C. Wainwright
05/11/20 Nomura Instinet
Protagonist Therapeutics price target raised to $33 from $29 at Nomura Instinet
04/30/20 Nomura Instinet
Protagonist shares offer 'asymmetric potential upside,' says Nomura Instinet
01/07/20 BTIG
Sarepta, Pacira, Protagonist named top 2020 Biotech picks at BTIG
PTGX Protagonist Therapeutics
$16.18 /

-0.2 (-1.22%)

PTGX Protagonist Therapeutics
$16.18 /

-0.2 (-1.22%)

Hot Stocks
Protagonist granted orphan status for polycythemia vera treatment » 10:08
06/15/20
06/15
10:08
06/15/20
10:08
PTGX

Protagonist Therapeutics

$16.17 /

-0.03 (-0.19%)

The FDA posted on its…

The FDA posted on its website that it granted Protagonist Therapeutics orphan status for its treatment of polycythemia vera.

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$16.17 /

-0.03 (-0.19%)

PTGX Protagonist Therapeutics
$16.17 /

-0.03 (-0.19%)

05/18/20 H.C. Wainwright
Protagonist Therapeutics price target raised to $28 from $23 at H.C. Wainwright
05/11/20 Nomura Instinet
Protagonist Therapeutics price target raised to $33 from $29 at Nomura Instinet
04/30/20 Nomura Instinet
Protagonist shares offer 'asymmetric potential upside,' says Nomura Instinet
01/07/20 BTIG
Sarepta, Pacira, Protagonist named top 2020 Biotech picks at BTIG
PTGX Protagonist Therapeutics
$16.17 /

-0.03 (-0.19%)

PTGX Protagonist Therapeutics
$16.17 /

-0.03 (-0.19%)

Conference/Events
European Hematology Association to hold virtual conference » 04:55
06/14/20
06/14
04:55
06/14/20
04:55
PTGX

Protagonist Therapeutics

$16.20 /

+0.58 (+3.71%)

25th EHA Annual Virtual…

25th EHA Annual Virtual Congress will be held on June 11-14. Webcast Link

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$16.20 /

+0.58 (+3.71%)

PTGX Protagonist Therapeutics
$16.20 /

+0.58 (+3.71%)

05/18/20 H.C. Wainwright
Protagonist Therapeutics price target raised to $28 from $23 at H.C. Wainwright
05/11/20 Nomura Instinet
Protagonist Therapeutics price target raised to $33 from $29 at Nomura Instinet
04/30/20 Nomura Instinet
Protagonist shares offer 'asymmetric potential upside,' says Nomura Instinet
01/07/20 BTIG
Sarepta, Pacira, Protagonist named top 2020 Biotech picks at BTIG
PTGX Protagonist Therapeutics
$16.20 /

+0.58 (+3.71%)

PTGX Protagonist Therapeutics
$16.20 /

+0.58 (+3.71%)

Conference/Events
European Hematology Association to hold virtual conference » 04:55
06/13/20
06/13
04:55
06/13/20
04:55
PTGX

Protagonist Therapeutics

$16.20 /

+0.58 (+3.71%)

25th EHA Annual Virtual…

25th EHA Annual Virtual Congress will be held on June 11-14. Webcast Link

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$16.20 /

+0.58 (+3.71%)

PTGX Protagonist Therapeutics
$16.20 /

+0.58 (+3.71%)

05/18/20 H.C. Wainwright
Protagonist Therapeutics price target raised to $28 from $23 at H.C. Wainwright
05/11/20 Nomura Instinet
Protagonist Therapeutics price target raised to $33 from $29 at Nomura Instinet
04/30/20 Nomura Instinet
Protagonist shares offer 'asymmetric potential upside,' says Nomura Instinet
01/07/20 BTIG
Sarepta, Pacira, Protagonist named top 2020 Biotech picks at BTIG
PTGX Protagonist Therapeutics
$16.20 /

+0.58 (+3.71%)

PTGX Protagonist Therapeutics
$16.20 /

+0.58 (+3.71%)

Conference/Events
European Hematology Association to hold virtual conference » 04:55
06/12/20
06/12
04:55
06/12/20
04:55
PTGX

Protagonist Therapeutics

$15.62 /

-0.6 (-3.70%)

25th EHA Annual Virtual…

25th EHA Annual Virtual Congress will be held on June 11-14. Webcast Link

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$15.62 /

-0.6 (-3.70%)

PTGX Protagonist Therapeutics
$15.62 /

-0.6 (-3.70%)

05/18/20 H.C. Wainwright
Protagonist Therapeutics price target raised to $28 from $23 at H.C. Wainwright
05/11/20 Nomura Instinet
Protagonist Therapeutics price target raised to $33 from $29 at Nomura Instinet
04/30/20 Nomura Instinet
Protagonist shares offer 'asymmetric potential upside,' says Nomura Instinet
01/07/20 BTIG
Sarepta, Pacira, Protagonist named top 2020 Biotech picks at BTIG
PTGX Protagonist Therapeutics
$15.62 /

-0.6 (-3.70%)

PTGX Protagonist Therapeutics
$15.62 /

-0.6 (-3.70%)

Conference/Events
European Hematology Association to hold virtual conference » 07:53
06/11/20
06/11
07:53
06/11/20
07:53
PTGX

Protagonist Therapeutics

$16.22 /

+0.16 (+1.00%)

25th EHA Annual Virtual…

25th EHA Annual Virtual Congress will be held on June 11-14. Webcast Link

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$16.22 /

+0.16 (+1.00%)

PTGX Protagonist Therapeutics
$16.22 /

+0.16 (+1.00%)

05/18/20 H.C. Wainwright
Protagonist Therapeutics price target raised to $28 from $23 at H.C. Wainwright
05/11/20 Nomura Instinet
Protagonist Therapeutics price target raised to $33 from $29 at Nomura Instinet
04/30/20 Nomura Instinet
Protagonist shares offer 'asymmetric potential upside,' says Nomura Instinet
01/07/20 BTIG
Sarepta, Pacira, Protagonist named top 2020 Biotech picks at BTIG
PTGX Protagonist Therapeutics
$16.22 /

+0.16 (+1.00%)

PTGX Protagonist Therapeutics
$16.22 /

+0.16 (+1.00%)

Options
Four new option listings on June 3rd » 08:30
06/03/20
06/03
08:30
06/03/20
08:30
GAN

Gan Limited

$21.80 /

-2.4 (-9.92%)

, PTGX

Protagonist Therapeutics

$16.76 /

+0.28 (+1.70%)

, SLQT

SelectQuote

$28.56 /

+0.21 (+0.74%)

, XAIR

Beyond Air

$7.12 /

+ (+0.00%)

New option listings for…

New option listings for June 3rd include GAN Ltd (GAN), Protagonist Therapeutics (PTGX), SelectQuote Inc (SLQT), and Beyond Air Inc (XAIR).

ShowHide Related Items >><<
XAIR Beyond Air
$7.12 /

+ (+0.00%)

PTGX Protagonist Therapeutics
$16.76 /

+0.28 (+1.70%)

GAN Gan Limited
$21.80 /

-2.4 (-9.92%)

GAN Gan Limited
$21.80 /

-2.4 (-9.92%)

05/07/20
Fly Intel: Top five analyst initiations
05/07/20 Craig-Hallum
Gan Limited initiated with a Buy at Craig-Hallum
05/07/20 B. Riley FBR
B. Riley FBR starts Gan with Buy on sports betting opportunity
05/07/20 B. Riley FBR
Gan Limited initiated with a Buy at B. Riley FBR
PTGX Protagonist Therapeutics
$16.76 /

+0.28 (+1.70%)

05/18/20 H.C. Wainwright
Protagonist Therapeutics price target raised to $28 from $23 at H.C. Wainwright
05/11/20 Nomura Instinet
Protagonist Therapeutics price target raised to $33 from $29 at Nomura Instinet
04/30/20 Nomura Instinet
Protagonist shares offer 'asymmetric potential upside,' says Nomura Instinet
01/07/20 BTIG
Sarepta, Pacira, Protagonist named top 2020 Biotech picks at BTIG
SLQT SelectQuote
$28.56 /

+0.21 (+0.74%)

XAIR Beyond Air
$7.12 /

+ (+0.00%)

10/21/19 Oppenheimer
Oppenheimer starts Beyond Air with Outperform rating, $9 price target
10/21/19 Oppenheimer
Beyond Air initiated with an Outperform at Oppenheimer
XAIR Beyond Air
$7.12 /

+ (+0.00%)

PTGX Protagonist Therapeutics
$16.76 /

+0.28 (+1.70%)

SLQT SelectQuote
$28.56 /

+0.21 (+0.74%)

Recommendations
Protagonist Therapeutics price target raised to $28 from $23 at H.C. Wainwright » 07:08
05/18/20
05/18
07:08
05/18/20
07:08
PTGX

Protagonist Therapeutics

$16.15 /

-0.14 (-0.86%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Douglas Tsao raised the firm's price target on Protagonist Therapeutics to $28 from $23 and reiterates a Buy rating on the shares. The company's data from the initial dose-finding portion of a Phase 2 study showed a 100% response rate in maintaining hematocrit less than 45% in polycythemia vera patients with none requiring phlebotomies, Tsao tells investors in a research note. The strength of the results and ongoing unmet need in polycythemia vera may qualify PTG-300 for Breakthrough designation with the FDA, says the analyst.

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$16.15 /

-0.14 (-0.86%)

PTGX Protagonist Therapeutics
$16.15 /

-0.14 (-0.86%)

05/11/20 Nomura Instinet
Protagonist Therapeutics price target raised to $33 from $29 at Nomura Instinet
04/30/20 Nomura Instinet
Protagonist shares offer 'asymmetric potential upside,' says Nomura Instinet
01/07/20 BTIG
Sarepta, Pacira, Protagonist named top 2020 Biotech picks at BTIG
12/04/19 Nomura Instinet
Nomura Instinet 'aggressive buyers' of Protagonist after yesterday's selloff
PTGX Protagonist Therapeutics
$16.15 /

-0.14 (-0.86%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.